NxStage Medical (NXTM) Sets New 1-Year High at $29.32

NxStage Medical, Inc. (NASDAQ:NXTM) reached a new 52-week high on Monday . The stock traded as high as $29.32 and last traded at $29.20, with a volume of 8721 shares traded. The stock had previously closed at $29.15.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a report on Wednesday, January 30th. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, December 21st. Finally, ValuEngine upgraded NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, October 12th.

Get NxStage Medical alerts:

The company has a market cap of $1.94 billion, a P/E ratio of -132.86 and a beta of 0.25.

NxStage Medical (NASDAQ:NXTM) last released its earnings results on Wednesday, November 7th. The medical device company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. The company had revenue of $108.12 million during the quarter, compared to analysts’ expectations of $108.07 million. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. As a group, research analysts anticipate that NxStage Medical, Inc. will post -0.01 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NXTM. Bank of America Corp DE raised its stake in NxStage Medical by 45.0% during the second quarter. Bank of America Corp DE now owns 48,434 shares of the medical device company’s stock valued at $1,351,000 after buying an additional 15,028 shares during the last quarter. Bank of New York Mellon Corp raised its stake in NxStage Medical by 5.2% during the second quarter. Bank of New York Mellon Corp now owns 605,270 shares of the medical device company’s stock valued at $16,888,000 after buying an additional 29,934 shares during the last quarter. Northern Trust Corp raised its stake in NxStage Medical by 3.0% during the second quarter. Northern Trust Corp now owns 885,227 shares of the medical device company’s stock valued at $24,697,000 after buying an additional 25,633 shares during the last quarter. Bank of Montreal Can raised its stake in NxStage Medical by 2.5% during the third quarter. Bank of Montreal Can now owns 426,725 shares of the medical device company’s stock valued at $11,901,000 after buying an additional 10,343 shares during the last quarter. Finally, Levin Capital Strategies L.P. raised its stake in NxStage Medical by 38.6% during the third quarter. Levin Capital Strategies L.P. now owns 21,018 shares of the medical device company’s stock valued at $586,000 after buying an additional 5,857 shares during the last quarter. Institutional investors own 83.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4125665/nxstage-medical-nxtm-sets-new-1-year-high-at-29-32.html.

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Read More: Leveraged Buyout (LBO) Explained